Cytokinetics, Inc. will be presenting four times at the 73rd Annual Scientific Session of the American College of Cardiology (ACC.24), scheduled to occur in Atlanta from April 6 to 8, 2024. Among the highlighted presentations is one on the efficacy and safety of Aficamten in patients with obstructive hypertrophic cardiomyopathy, presented by Dr. Sara Saberi from the University of Michigan Health Frankel Cardiovascular Center. Other topics include the impact of Beta Blocker use on atrial fibrillation post-Septal Myectomy, medication patterns before and after Septal Myectomy in obstructive hypertrophic cardiomyopathy patients, and a study on racial and ethnic differences in cardiovascular outcomes for those diagnosed with the condition.
Cytokinetics is a biopharmaceutical company focusing on the development of muscle activators and inhibitors to treat diseases where cardiac muscle performance is compromised. It is advancing aficamten, a cardiac myosin inhibitor, through clinical trials, including SEQUOIA-HCM for obstructive hypertrophic cardiomyopathy and additional studies for non-obstructive forms of the condition. The company is also developing other potential treatments like omecamtiv mecarbil for heart failure and CK-586 and CK-136 for various cardiac conditions.
Cytokinetics continues to be a key player in the realm of cardiovascular biopharmaceuticals, emphasizing muscle biology and myocardial function, with ongoing initiatives to enhance its research, development, and commercialization efforts in this area. For more information, Cytokinetics can be followed on various social media platforms and its official website.